Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study

Not Applicable

Terminated

Conditions: Crohn Disease

Interventions: Device: Vagal Nerve Stimulator

Registration Number: NCT05165108

Lead Sponsor: Indiana University

Brief Summary: To assess the safety and efficacy of transcutaneous vagal stimulation in adult patients with active Crohn's disease.

Detailed Description: Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation in the digestive tract. The pathogenesis of IBD involves immunological, genetic and environmental factors. Currently there is no cure for Crohn's disease and available medical and surgical treatments are expensive and often associated with significant side effects. Anti-tumor necrosis factor alpha (anti-TNF-α) agents are widely used for treatment of Crohn's disease. Electrical neuromodulation is a new treatment approach of bioelectronic medicine, involving molecular medicine, neuroscience, and bioengineering. Multiple possible mechanisms have been proposed for electrical neuromodulation in GI diseases, including central, autonomic, and/or enteric mechanisms. Vagal tone is significantly blunted in IBD and is associated with high TNF- α levels. Animal and preliminary human studies have demonstrated that electrical vagal nerve stimulation (VNS), including non-invasive vagal stimulation (nVNS), exerts an anti-inflammatory effect by harnessing the cholinergic anti-inflammatory pathway. In healthy humans nVNS has been shown to decrease tumor necrosis factor-α levels. Invasive VNS has been shown to improve inflammation in preliminary studies in patients with Crohn's disease.

Adult patients with active Crohn's disease will be asked to self-administer transcutaneous vagal nerve stimulation three times per day for 16 weeks. Inflammatory laboratory markers will be compared for each patient against their baseline levels to determine if the intervention helps reduce inflammation cause by their Crohn's disease. Questionnaires will be administered to evaluation their symptoms, and quality of life over the 16 week treatment period.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 4

Inclusion Criteria

Crohn's disease diagnosis for at least 3 months, confirmed by clinical, biochemical, and endoscopic evaluations.
Patients with CD involving the small bowel and / or colon with active symptoms with Crohn's Disease Activity Index (CDAI) > 220 despite at least one conventional therapy (corticosteroids and/or immunosuppressives) with a stable dose will be included.
Elevated Fecal calprotectin ≥ 200 micro g/g within the past 4 weeks prior to enrollment
If on corticosteroids, the dose must be stable and ≤ 20mg/day prednisone or equivalent for at least 14 days before entry into study.
If on background immunosuppressive treatment the dose must be stable with the following parameters:
56 days (8 weeks) for Immunomodulators (methotrexate, 6-MP, Azathioprine) and small molecules (upadacitinib)
112 84 days (16 12 weeks) for biologics (Infliximab, Adalimumab, Vedolizumab, Ustekinumab, another biologic Risankizumab)
Clinical laboratory evaluations (including a chemistry panel, complete blood count [CBC], and urinalysis [UA]) within the reference range for the test laboratory, unless a typical consequence of CD or deemed not clinically significant by the Investigator.
Colonoscopy within the previous 1 year with no evidence of colonic dysplasia or cancer.
Able and willing to give written informed consent and comply with the requirements of the study protocol.

Exclusion Criteria

Expectation to increase corticosteroids and/or immunosuppressive treatment
Presence of bowel stricture with pre-stenotic dilatation
Presence of intra-abdominal or perirectal abscess
Crohn's Disease Activity Index (CDAI) < 220
Fistula with clinical or radiological evidence of abscess
Perianal CD with or without rectal involvement
Ileostomy, colostomy, enteral or parenteral feeding
Short gut syndrome.
Clinical condition medically or surgically unstable that, at the discretion of the investigator would not be compatible with the patient's participation in the study
Any malignant neoplasia, in the year prior to screening ,except for nonmelanoma skin cancer.
Active treatment with antibiotics
Presence of active intestinal infection or documented infection by stool PCR or culture analysis in the previous 6 weeks
Continuous treatment with an anti-cholinergic medication, including over the counter medications.
Implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators.
Current tobacco or nicotine user within the past 4 weeks (to limit potential confounding effects of exposure to nicotine)
Bowel resection surgery within past 90 days prior to study enrollment and on no conventional IBD therapy, or planned surgery within the course of the study
Participation in any other Investigational drug and/or treatment currently or planned during the length of the study 19. Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to a study intervention 20. Pregnancy or Lactation 21. Comorbid disease with high likelihood of requiring corticosteroid use 22. Inability to comply with study and follow-up procedures 23. Non-English speaking. 24. Known cardiac condition causing or with potential to cause arrhythmia 25. Patients diagnosed with narrowing of the arteries (carotid atherosclerosis) 26. Patients who have had surgery to cut the Vagus nerve in the neck (cervical vagotomy) 27. Patients with clinically significant untreated hypertension, hypotension, bradycardia, or tachycardia.
Have a metallic device such as a stent, bone plate or bone screw implanted at or near their neck.
Are using another device at the same time (e.g., TENS Unit, muscle stimulator)

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Non-Invasive VNS	Vagal Nerve Stimulator	Non-Invasive VNS will decrease inflammation in people with Crohn's disease leading to decrease in inflammatory markers and symptoms of disease.

Primary Outcome Measures

Name	Time	Method
Change in Fecal Calprotectin From Baseline to 16 Weeks	Baseline and 16 weeks	This test can identify the level of inflammation in the colon of a person with Crohn's Disease. If a person diagnosed with Crohn's Disease subsequently shows low levels (50 -200 ug/mg) of fecal calprotectin, this means that the inflammation is being controlled, so the treatment regime is working.

Secondary Outcome Measures

Name	Time	Method
Change in Crohn's Disease Activity Index (CDAI) From Baseline to 16 Weeks	Baseline and 16 Weeks	CDAI range is minimum 0 and maximum 450. Zero is best score. Four hundred and fifty is the worst score. Lowering the CDAI score by 70 points or more is the goal for this study. A CDAI score of \< or = 150 is considered remission.
Change in Serum Cytokine Levels From Baseline to 16 Weeks	16 Weeks	Cytokine levels within the blood will be assessed and compared to baseline levels. The cytokines being assayed include C- reactive protein, tumor necrosis factor-alpha, Interferon-gamma, Transforming Growth Factor-beta and Interleukins (IL) - 1, 6, 10, 12, 17, 21, 23. (all cytokines will be presented at pg/mL)
Evaluating Change in HRV From Baseline Until Study Completion.	16 Weeks	Heart Rate Variability (HRV)
Change in Insulin Levels After First Stimulation	Baseline Visit	Serum Insulin levels in the blood will be assessed and compared prior to stimulation, and at 20 minutes and 40 minutes after the stimulation. (presented as mCU/mL)